We offer healthcare providers a comprehensive and advanced portfolio of over 500 ready-to-order disease state testing solutions encompassing all major testing methodologies, including next-generation sequencing (NGS) and broad panel DNA and RNA testing, as well as a full complement of hematologic testing to meet your and your patients’ needs.
At NeoGenomics, we understand the needs of pharma and biotech, and we work closely with our partners to develop life-saving therapies. Our comprehensive suite of advanced multi-modal solutions and validated methodologies, along with a dedicated team of MDs, PhDs, and project managers, ensure optimized clinical outcomes, reduce timelines, and drive innovation.
We understand the vital role that data play in precision oncology. Drawing upon one of the largest oncology databases with over 2 million unique patient profiles, we harness the power of this data to facilitate the discovery and development of new therapeutic options, support clinical trial matching, and assess therapy outcomes to deliver personalized patient care.
Our legacy
Cancer’s questions occupy every moment of our days. Why? Because we know that every minute we spend consumed by answers, might mean one more life saved. Since we started in 1999, we have grown to an inspiring team of 2,200 worldwide, spanning 13 locations across 2 continents, with more than 120 MDs and PhDs on our staff.
With an ever-expanding portfolio of solutions, each year we deliver over 1.7 million cancer-related tests, including more than 100,000 NGS tests, and we work with about 4,400 medical sites ─ providing answers to more than 500,000 patients.
Our leadership
Every member of the NeoGenomics team is devoted to our central mission: transforming the fight against cancer by advancing patient care ─ an ideal that starts with our leadership team.